<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768910</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-2011-0346/PB_2016-00872</org_study_id>
    <nct_id>NCT01768910</nct_id>
  </id_info>
  <brief_title>Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction</brief_title>
  <official_title>The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Balgrist University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide profound insight into the supraspinal neuronal&#xD;
      mechanisms and networks responsible for lower urinary tract (LUT) control and to verify,&#xD;
      amend or adjust neuronal circuitry models established from findings in healthy subjects in&#xD;
      the context of neurogenic and non-neurogenic LUT dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subject recruitment will be performed within the Neuro-Urology outpatient clinic at the&#xD;
      Balgrist University Hospital and in collaboration with the Departments of Neurology, Urology&#xD;
      and Gynecology at the University Hospital ZÃ¼rich.&#xD;
&#xD;
      The following subject groups will be recruited: 1) healthy controls (n=22), Non-neurogenic&#xD;
      overactive bladder (NNOAB) patients (n=20), multiple sclerosis (MS) patients with OAB (n=15),&#xD;
      MS patients without OAB (n=15), spinal cord injury (SCI) patients with neurogenic detrusor&#xD;
      overactivity (n=24).&#xD;
&#xD;
      After inclusion, all subjects and patients will undergo one to two functional magnetic&#xD;
      resonance imaging (fMRI) sessions. NNOAB patients might undergo an additional fMRI session&#xD;
      after receiving overactive bladder (OAB) treatment (such as antimuscarinics, intradetrusor&#xD;
      injections of botulinum toxin type A). Spinal cord injury (SCI) patients with neurogenic&#xD;
      detrusor overactivity will undergo an additional fMRI session 5-7 weeks after intradetrusor&#xD;
      injections of botulinum toxin type A.&#xD;
&#xD;
      High-resolution anatomical images and functional blood-oxygen-level-dependent (BOLD)-signal&#xD;
      sensitive images will be acquired. In addition to the fMRI, diffusion tensor imaging (DTI)&#xD;
      sequences will be recorded after the anatomical scans to provide information about the&#xD;
      structural supraspinal connectivity.&#xD;
&#xD;
      Study endpoints are changes of the BOLD signal in regard to location and intensity,&#xD;
      structural and functional connectivity (FC) between previously described supraspinal centers&#xD;
      involved in LUT control, and statistical differences of changes in BOLD signals, structural&#xD;
      and functional connectivity between patients and healthy controls.&#xD;
&#xD;
      All acquired fMRI data will be transferred to an off-line workstation running BrainVoyager QX&#xD;
      or Statistical Parametric Mapping (SPM) Version 8. The functional data will be pre-processed&#xD;
      for motion correction, spatial smoothing, linear trend removal, and temporal high-pass&#xD;
      filtering. With both programs statistical analysis and graphical presentation of the results&#xD;
      can be performed.&#xD;
&#xD;
      The DTI records will be evaluated with SPM8, BrainVoyager QX or other programs like&#xD;
      Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL) and&#xD;
      DTI-Studio. To estimate FC we will use SPM8 or the brain connectivity toolbox. Both softwares&#xD;
      allow the estimation of rest- and task-related connectivity on single subject and group level&#xD;
      with corrected statistical threshold.&#xD;
&#xD;
      Overall, 96 subjects for the main study are estimated to be sufficient to demonstrate&#xD;
      significant differences between groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">July 17, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bold signal</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>During fMRI measurements the changes of BOLD signal intensity in respect to certain supraspinal areas (e.g. pons, insula, anterior cingulate cortex, thalamus, supplementary motor area, prefrontal cortex) will be evaluated.&#xD;
Variables are age, bladder volume, urgency and attention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural and functional connectivity</measure>
    <time_frame>baseline and after potential OAB treatment</time_frame>
    <description>Acquired data from the above mentioned measurements will be used to analyze structural and functional connectivity between supraspinal areas involved in the LUT control, especially between prefrontal, thalamus, insula, and anterior cingulate cortex.&#xD;
Variables are age, bladder volume, urgency and attention. Correlations of neuronal activity from the fMRI-data will be estimated using SPM8, brain connectivity tool box.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>3 years</time_frame>
    <description>Pain, Lower urinary tract infection</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Neurogenic Lower Urinary Tract Dysfunction</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Overactive Bladder</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS with OAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS without OAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNOAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCI with neurogenic detrusor overactivity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fMRI</intervention_name>
    <description>2 measurements using functional magnetic resonance imaging in a 3T scanner</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>MS with OAB</arm_group_label>
    <arm_group_label>MS without OAB</arm_group_label>
    <arm_group_label>NNOAB</arm_group_label>
    <arm_group_label>SCI with neurogenic detrusor overactivity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bladder filling</intervention_name>
    <description>Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>MS with OAB</arm_group_label>
    <arm_group_label>MS without OAB</arm_group_label>
    <arm_group_label>NNOAB</arm_group_label>
    <arm_group_label>SCI with neurogenic detrusor overactivity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bladder cooling</intervention_name>
    <description>Retrograde bladder filling via transurethral catheter with 4-8Â°C saline during each of the fMRI measurements.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>MS with OAB</arm_group_label>
    <arm_group_label>MS without OAB</arm_group_label>
    <arm_group_label>NNOAB</arm_group_label>
    <arm_group_label>SCI with neurogenic detrusor overactivity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>additional post-treatment fMRI scan</intervention_name>
    <description>Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.</description>
    <arm_group_label>NNOAB</arm_group_label>
    <arm_group_label>SCI with neurogenic detrusor overactivity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  MR suitability&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  unimpaired LUT function&#xD;
&#xD;
        MS patients with OAB&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  MR suitability&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  diagnosis of MS according to the McDonald criteria&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) â¤ 6&#xD;
&#xD;
          -  OAB symptoms since &gt; 6 months&#xD;
&#xD;
               -  â¥ 3 episodes of urinary urgency&#xD;
&#xD;
               -  frequency &gt; 8/24h&#xD;
&#xD;
          -  with or without detrusor overactivity&#xD;
&#xD;
        MS patients without OAB&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  MR suitability&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  diagnosis of MS according to the McDonald criteria&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) â¤ 6&#xD;
&#xD;
        Patients with NNOAB&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  MR suitability&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  idiopathic OAB symptoms since &gt; 6 months&#xD;
&#xD;
               -  â¥ 3 episodes of urinary urgency&#xD;
&#xD;
               -  frequency &gt; 8/24h&#xD;
&#xD;
          -  refractory to antimuscarinic treatment for â¥ 1 month&#xD;
&#xD;
          -  indication for intradetrusor injections of Botulinumtoxin Type A&#xD;
&#xD;
          -  willingness and ability to perform self-catheterization&#xD;
&#xD;
        SCI patients with neurogenic detrusor overactivity&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  MR suitability&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  neurogenic detrusor overactivity due to SCI&#xD;
&#xD;
          -  indication for intradetrusor injections of botulinum toxin type A&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
          -  impaired LUT function&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  no informed consent&#xD;
&#xD;
          -  any craniocerebral injury or surgery&#xD;
&#xD;
          -  any permanent ferromagnetic implant&#xD;
&#xD;
          -  any previous surgery of the LUT or genitalia&#xD;
&#xD;
          -  any anatomical anomaly of the LUT or genitalia&#xD;
&#xD;
          -  any LUT malignancy&#xD;
&#xD;
          -  postvoid residual urine volume (PVR) &gt; 150ml&#xD;
&#xD;
          -  current urinary tract infection&#xD;
&#xD;
          -  any LUT symptoms&#xD;
&#xD;
               -  â¥ 3 episodes of urinary urgency&#xD;
&#xD;
               -  frequency &gt; 8/24h&#xD;
&#xD;
        MS patients with OAB&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  any permanent ferromagnetic implant&#xD;
&#xD;
          -  any neurological or psychological disease despite MS&#xD;
&#xD;
          -  any craniocerebral injury or surgery&#xD;
&#xD;
          -  any previous surgery of the LUT or genitalia&#xD;
&#xD;
          -  any anatomical anomaly or malignancy of the LUT or genitalia&#xD;
&#xD;
          -  any metabolic disease&#xD;
&#xD;
          -  PVR &gt; 150ml&#xD;
&#xD;
          -  any concomitant treatment for the LUT (e.g. neuromodulation)&#xD;
&#xD;
          -  Stress urinary incontinence&#xD;
&#xD;
          -  any condition other than MS that might explain OAB symptoms&#xD;
&#xD;
          -  current urinary tract infection&#xD;
&#xD;
          -  indwelling catheters or the necessity to perform self-catheterization&#xD;
&#xD;
        MS patients without OAB&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  any permanent ferromagnetic implant&#xD;
&#xD;
          -  any neurological or psychological disease despite MS&#xD;
&#xD;
          -  any craniocerebral injury or surgery&#xD;
&#xD;
          -  any previous surgery of the LUT or genitalia&#xD;
&#xD;
          -  any anatomical anomaly or malignancy of the LUT or genitalia&#xD;
&#xD;
          -  any metabolic disease&#xD;
&#xD;
          -  PVR &gt; 150ml&#xD;
&#xD;
          -  any concomitant treatment for the LUT (e.g. neuromodulation)&#xD;
&#xD;
          -  Stress urinary incontinence&#xD;
&#xD;
          -  any LUT symptoms&#xD;
&#xD;
               -  â¥ 3 episodes of urinary urgency&#xD;
&#xD;
               -  frequency &gt; 8/24h&#xD;
&#xD;
          -  indwelling catheters or the necessity to perform self-catheterization&#xD;
&#xD;
          -  detrusor overactivity&#xD;
&#xD;
          -  current urinary tract infection&#xD;
&#xD;
        Patients with NNOAB&#xD;
&#xD;
          -  pregnancy or planned within next 8 months, breast feeding&#xD;
&#xD;
          -  any permanent ferromagnetic implant&#xD;
&#xD;
          -  any neurological, psychological, metabolic or cardiovascular disease&#xD;
&#xD;
          -  any craniocerebral injury or surgery&#xD;
&#xD;
          -  any previous surgery of the LUT or genitalia within the last year or that is related&#xD;
             to the OAB symptoms&#xD;
&#xD;
          -  any anatomical anomaly or malignancy of the LUT or genitalia&#xD;
&#xD;
          -  PVR &gt; 150ml&#xD;
&#xD;
          -  Stress urinary incontinence&#xD;
&#xD;
          -  indwelling catheters or the necessity to perform self-catheterization&#xD;
&#xD;
          -  any concomitant treatment for the LUT (e.g. neuromodulation)&#xD;
&#xD;
          -  current urinary tract infection&#xD;
&#xD;
        SCI patients with neurogenic detrusor overactivity&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  any permanent ferromagnetic implant&#xD;
&#xD;
          -  any neurological or psychological disease despite SCI&#xD;
&#xD;
          -  any craniocerebral injury or surgery&#xD;
&#xD;
          -  any previous surgery of LUT of genitalia&#xD;
&#xD;
          -  any anatomical anomaly or malignancy of the LUT or genitalia&#xD;
&#xD;
          -  any metabolic disease&#xD;
&#xD;
          -  any concomitant treatment for the LUT (e.g. neuromodulation)&#xD;
&#xD;
          -  current urinary tract infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Mehnert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuro-Urology, Spinal Cord Injury Center &amp; Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas M Kessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuro-Urology, Spinal Cord Injury Center &amp; Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Spyros Kollias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Neuroradiology, University Hospital Zurich, Sternwartstrasse 6, 8091 Zurich, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuro-Urology, Spinal Cord Injury Center &amp; Research, University of ZÃ¼rich, Balgrist University Hospital</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital ZÃ¼rich</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Walter M, Michels L, Kollias S, van Kerrebroeck PE, Kessler TM, Mehnert U. Protocol for a prospective neuroimaging study investigating the supraspinal control of lower urinary tract function in healthy controls and patients with non-neurogenic lower urinary tract symptoms. BMJ Open. 2014 May 21;4(5):e004357. doi: 10.1136/bmjopen-2013-004357. Erratum in: BMJ Open. 2014;4(6):e004357.</citation>
    <PMID>24848086</PMID>
  </results_reference>
  <results_reference>
    <citation>Leitner L, Walter M, Freund P, Mehnert U, Michels L, Kollias S, Kessler TM. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity. BMC Urol. 2014 Aug 18;14:68. doi: 10.1186/1471-2490-14-68.</citation>
    <PMID>25132340</PMID>
  </results_reference>
  <results_reference>
    <citation>Leitner L, Walter M, Jarrahi B, Wanek J, Diefenbacher J, Michels L, Liechti MD, Kollias SS, Kessler TM, Mehnert U. A novel infusion-drainage device to assess lower urinary tract function in neuro-imaging. BJU Int. 2017 Feb;119(2):305-316. doi: 10.1111/bju.13655. Epub 2016 Oct 20.</citation>
    <PMID>27617867</PMID>
  </results_reference>
  <results_reference>
    <citation>Walter M, Leitner L, Michels L, Liechti MD, Freund P, Kessler TM, Kollias S, Mehnert U. Reliability of supraspinal correlates to lower urinary tract stimulation in healthy participants - A fMRI study. Neuroimage. 2019 May 1;191:481-492. doi: 10.1016/j.neuroimage.2019.02.031. Epub 2019 Feb 15.</citation>
    <PMID>30776530</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lower urinary tract</keyword>
  <keyword>bladder</keyword>
  <keyword>supraspinal control</keyword>
  <keyword>neuroimaging</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>diffusion tensor imaging</keyword>
  <keyword>functional connectivity</keyword>
  <keyword>neurogenic lower urinary tract dysfunction</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

